Stock Traders Buy High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) saw unusually large options trading activity on Wednesday. Stock investors bought 4,063 put options on the stock. This represents an increase of approximately 2,362% compared to the average daily volume of 165 put options.

Xenon Pharmaceuticals Stock Performance

Shares of NASDAQ XENE opened at $55.88 on Thursday. The stock has a market cap of $5.40 billion, a P/E ratio of -11.89 and a beta of 0.65. The firm has a 50 day moving average price of $55.59 and a 200 day moving average price of $46.99. Xenon Pharmaceuticals has a 52-week low of $28.19 and a 52-week high of $63.95.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($1.17). During the same quarter last year, the firm posted ($0.83) EPS. Analysts predict that Xenon Pharmaceuticals will post -4.89 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on XENE. Morgan Stanley set a $97.00 price target on shares of Xenon Pharmaceuticals in a research report on Monday, March 9th. Royal Bank Of Canada lifted their price target on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “outperform” rating in a research report on Friday, May 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a report on Wednesday, April 8th. Robert W. Baird boosted their price objective on shares of Xenon Pharmaceuticals from $63.00 to $97.00 and gave the company an “outperform” rating in a report on Monday, March 9th. Finally, Jefferies Financial Group set a $100.00 price objective on shares of Xenon Pharmaceuticals in a report on Monday, March 9th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $77.07.

Trending Headlines about Xenon Pharmaceuticals

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: JPMorgan Chase & Co. raised its price target on Xenon Pharmaceuticals from $77 to $80 and reiterated an overweight rating, signaling more upside from current levels. Benzinga
• Positive Sentiment: HC Wainwright kept a buy rating and $74 price target while lifting earnings estimates across several future periods, including Q2, Q3, Q4 2026, FY2026, FY2027, FY2028, FY2029, and FY2030, suggesting improved long-term expectations for the company. MarketBeat XENE report
• Neutral Sentiment: The company’s latest earnings were in line with consensus, which helps support the stock but was not the main catalyst behind the move. MarketBeat XENE report

Insider Transactions at Xenon Pharmaceuticals

In other news, insider Andrea Difabio sold 1,342 shares of Xenon Pharmaceuticals stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $55.23, for a total transaction of $74,118.66. Following the completion of the sale, the insider owned 7,301 shares in the company, valued at $403,234.23. The trade was a 15.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Christopher John Kenney sold 1,410 shares of Xenon Pharmaceuticals stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $55.23, for a total transaction of $77,874.30. Following the sale, the insider owned 7,069 shares of the company’s stock, valued at approximately $390,420.87. This represents a 16.63% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 296,707 shares of company stock worth $17,845,365 in the last quarter. 4.07% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Neo Ivy Capital Management bought a new position in Xenon Pharmaceuticals in the third quarter valued at approximately $2,001,000. JPMorgan Chase & Co. lifted its stake in Xenon Pharmaceuticals by 11.3% in the third quarter. JPMorgan Chase & Co. now owns 1,399,033 shares of the biopharmaceutical company’s stock valued at $56,171,000 after buying an additional 142,452 shares in the last quarter. Assenagon Asset Management S.A. bought a new position in Xenon Pharmaceuticals in the fourth quarter valued at approximately $5,342,000. HighVista Strategies LLC lifted its stake in Xenon Pharmaceuticals by 80.2% in the third quarter. HighVista Strategies LLC now owns 82,190 shares of the biopharmaceutical company’s stock valued at $3,300,000 after buying an additional 36,570 shares in the last quarter. Finally, Peregrine Capital Management LLC bought a new position in Xenon Pharmaceuticals in the fourth quarter valued at approximately $7,837,000. Institutional investors own 95.45% of the company’s stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.